Want to see HK:6896 full AI Analyst Report?
6896 Stock Chart & Stats
HK$3.07
-HK$0.01(-0.32%)
At close: 4:00 PM EST
HK$3.07
-HK$0.01(-0.32%)
Day’s Range― - ―
52-Week RangeHK$2.88 - HK$4.98
Previous CloseN/A
Volume368.50K
Average Volume (3M)691.97K
Market Cap
HK$2.35B
Enterprise ValueHK$1.50B
Total Cash (Recent Filing)HK$1.08B
Total Debt (Recent Filing)HK$584.52M
Price to Earnings (P/E)8.3
Beta0.20
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield10.69%
Share Statistics
EPS (TTM)0.33
Shares Outstanding739,302,000
10 Day Avg. Volume656,610
30 Day Avg. Volume691,973
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)1.47
Price to Sales (P/S)2.15
P/FCF Ratio25.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross And Net MarginsSustained, very high gross and net margins point to durable pricing power and efficient production. This margin buffer supports profitability through demand cycles, funds reinvestment or dividends, and makes the business less sensitive to modest cost or volume shocks over the medium term.
Established Brand And Retail DistributionA recognized consumer healthcare brand combined with broad retail channel coverage (supermarkets, pharmacies, convenience stores) supports repeat purchases and shelf presence. This entrenched go-to-market setup sustains revenue resilience and competitive advantage in consumer staples over months.
Healthy Returns On Equity HistoricallyConsistently mid-teens to low-20s ROE implies efficient capital allocation and profitable operations, enabling dividend capacity and reinvestment. Even with a 2025 dip, this track record suggests structural profitability that can compound value over subsequent quarters if operational stability returns.
Bears Say
Sharp Cash Generation DeteriorationA large year-over-year drop in operating and free cash flow signals weaker cash conversion and potential working-capital stress or one-off outflows. Lower cash inflows limit flexibility for capex, debt servicing, and dividends, raising medium-term financing and operational risk if trends persist.
Material Revenue And EPS DeclinesSignificant revenue and EPS contraction indicate demand volatility or market share pressures. Recurrent top-line weakness undermines scale economies and makes margin maintenance harder, reducing long-term earnings visibility and the company’s ability to grow or sustain cash returns to shareholders.
Rising Leverage Reduces FlexibilityAn uptick in leverage tightens financial flexibility and increases interest and refinancing risk if earnings weaken. With cash generation down, higher leverage amplifies vulnerability to shocks and limits capacity for strategic investments or cushioning dividend policy over the medium term.
Golden Throat Holdings Group Co Ltd News
6896 FAQ
What was Golden Throat Holdings Group Co Ltd’s price range in the past 12 months?
Golden Throat Holdings Group Co Ltd lowest stock price was HK$2.88 and its highest was HK$4.98 in the past 12 months.
What is Golden Throat Holdings Group Co Ltd’s market cap?
Golden Throat Holdings Group Co Ltd’s market cap is HK$2.35B.
When is Golden Throat Holdings Group Co Ltd’s upcoming earnings report date?
Golden Throat Holdings Group Co Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 20 days.
How were Golden Throat Holdings Group Co Ltd’s earnings last quarter?
Golden Throat Holdings Group Co Ltd released its earnings results on Mar 27, 2026. The company reported HK$0.248 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.248.
Is Golden Throat Holdings Group Co Ltd overvalued?
According to Wall Street analysts Golden Throat Holdings Group Co Ltd’s price is currently Overvalued.
Does Golden Throat Holdings Group Co Ltd pay dividends?
Golden Throat Holdings Group Co Ltd pays a Annually dividend of HK$0.34 which represents an annual dividend yield of 10.69%. See more information on Golden Throat Holdings Group Co Ltd dividends here
What is Golden Throat Holdings Group Co Ltd’s EPS estimate?
Golden Throat Holdings Group Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Golden Throat Holdings Group Co Ltd have?
Golden Throat Holdings Group Co Ltd has 739,302,000 shares outstanding.
What happened to Golden Throat Holdings Group Co Ltd’s price movement after its last earnings report?
Golden Throat Holdings Group Co Ltd reported an EPS of HK$0.248 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.398%.
Which hedge fund is a major shareholder of Golden Throat Holdings Group Co Ltd?
Currently, no hedge funds are holding shares in HK:6896
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Golden Throat Holdings Group Co Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.84%
12-Months-Change
Fundamentals
Return on Equity
10.69%
Trailing 12-Months
Asset Growth
6.42%
Trailing 12-Months
Company Description
Golden Throat Holdings Group Co Ltd
Golden Throat Holdings Group Company Limited operates as an investment holding entity primarily engaged in the production and distribution of pharmaceutical goods, health-focused foods, and various other products within the People's Republic of China. Among its offerings are the widely recognized Golden Throat lozenges, an over-the-counter remedy designed to alleviate discomfort from sore and dry throats, as well as hoarseness often stemming from acute pharyngitis. The company further expands its Golden Throat lozenge line with products like Dule lozenges and their sugar-free counterparts, available in diverse flavors including orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn. Additionally, Golden Throat manufactures the Yinxingye tablet, formulated to enhance blood circulation, disperse blood stasis, and clear energy pathways. Its product portfolio also encompasses herbal vegetable beverages, crafted to provide vocal comfort and soothe irritated throats. Beyond its domestic market, the company extends its reach globally, exporting its range of products to countries and regions such as the United States, Canada, Russia, the European Union, Australia, Southeast Asia, the Middle East, Mexico, and across Africa. Established in 1956, Golden Throat Holdings Group Company Limited maintains its corporate headquarters in Liuzhou, within the People's Republic of China.
Technical Analysis
China Traditional Chinese Medicine Holdings Co
―
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Pak Fah Yeow International Limited
―
Jacobson Pharma Corporation Limited
―